Zymeworks (ZYME) Long-Term Investments (2021 - 2026)
Zymeworks recorded quarterly Long-Term Investments of $39.1 million in Q1 2026, down 6.39% quarter-over-quarter from $41.8 million in Q4 2025, and down 30.55% year-over-year from $56.3 million in Q1 2025.
Zymeworks' Long-Term Investments history runs 6 years deep, the most recent figure standing at $39.1 million for Q1 2026.
- In Q1 2026, Long-Term Investments fell 30.55% year-over-year to $39.1 million; the TTM figure through Mar 2026 stood at $39.1 million (down 30.55% YoY), while the FY2025 annual figure was $41.8 million, down 57.55% from the prior year.
- Long-Term Investments came in at $39.1 million for Q1 2026 at Zymeworks, down from $41.8 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $98.4 million in Q4 2024 to a low of $886000.0 in Q3 2022.
- A 5-year average of $59.9 million and a median of $65.8 million in 2024 frame the typical range for Long-Term Investments.
- Across the five-year window, Long-Term Investments jumped 10698.42% in 2023 and sank 57.55% in 2025, its largest moves.
- Zymeworks' Long-Term Investments stood at $886000.0 in 2022, then surged by 9147.18% to $81.9 million in 2023, then grew by 20.14% to $98.4 million in 2024, then sank by 57.55% to $41.8 million in 2025, then fell by 6.39% to $39.1 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $39.1 million, $41.8 million, and $47.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 39.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.12 Mn |
| Dec 31, 2025 | 41.79 Mn |
| Sep 30, 2025 | 47.43 Mn |
| Jun 30, 2025 | 52.00 Mn |
| Mar 31, 2025 | 56.32 Mn |
| Dec 31, 2024 | 98.43 Mn |
| Sep 30, 2024 | 77.67 Mn |
| Jun 30, 2024 | 65.79 Mn |
| Mar 31, 2024 | 75.45 Mn |
| Dec 31, 2023 | 81.93 Mn |
| Sep 30, 2023 | 95.67 Mn |
| Jun 30, 2023 | 92.24 Mn |
| Mar 31, 2023 | 72.47 Mn |
| Dec 31, 2022 | 886,000.00 |
| Sep 30, 2022 | 886,000.00 |
| Dec 31, 2021 | 886,000.00 |